Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clonixin is a nonsteroidal anti-inflammatory drug (NSAID) of the anilino-nicotinic acid derivative class, used primarily for its analgesic, anti-inflammatory, and antipyretic effects. It is indicated for the relief of pain associated with arthritis, migraines, soft tissue disorders, headaches, muscle aches, joint pain, dental and ear pain, dysmenorrhea (menstrual cramps), post-traumatic and post-surgical pain. Clonixin acts by inhibiting cyclooxygenase enzymes (COX-1 and COX-2), thereby reducing prostaglandin synthesis which mediates inflammation and pain. It also exhibits some platelet-inhibitory activity. The lysine salt form (lysine clonixinate) is commonly used in clinical practice[1][2][3][4][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clonixin.